Saturday 17 October 2026
Export GRDN’s income statement to Excel — free account
Guardian Pharmacy Services, Inc.
GRDN Healthcare Medical Care Facilities
Guardian Pharmacy Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.16%, EPS grew 133.3% and free cash flow grew 60.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
39.41
0.27
−0.68%
Follow GRDN
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
Piotroski F-Score |
7 | — | — |
P/E ratio |
38.09 | 0.00 | 0.00 |
P/S ratio |
1.30 | 1.02 | 0.00 |
Altman Z-Score |
10.28 | 7.70 | — |
P/FCF ratio |
23.26 | 30.20 | 0.00 |
Altman Z″-Score (non-manufacturers) |
3.85 | (0.06) | — |
Beneish M-Score |
(2.95) | (4.15) | — |
P/Operating CF |
54.25 | 56.24 | 0.00 |
P/B ratio |
8.61 | 8.38 | 0.00 |
Price to Tangible BV |
15.68 | 19.10 | 0.00 |
EV/Sales |
1.28 | 1.05 | 0.00 |
EV/EBITDA |
19.47 | 0.00 | 0.00 |
EV/Operating CF |
18.46 | 22.26 | 0.00 |
EV/FCF |
22.92 | 31.02 | 0.00 |
Quick Ratio |
1.04 | 0.71 | 0.57 |
Current Ratio |
1.38 | 1.05 | 0.94 |
Net Debt/EBITDA |
(0.69) | 0.11 | 0.46 |
Debt/Assets |
0.00% | 0.00% | 10.32% |
Debt/Equity |
0.00 | 0.00 | 0.47 |
Asset Turnover |
3.95 | 4.15 | 0.00 |
Operating CF/Net income |
2.04 | (0.53) | 0.00 |
Capex/Depreciation |
(0.88) | (0.83) | (0.80) |
Interest Coverage |
109.33 | (19.19) | 14.32 |
| 26.76% | (104.89%) | — | |
| 13.42% | (37.18%) | — | |
ROIC |
29.83% | (27.06%) | 29.38% |
Return on Tangible Assets |
42.27% | (190.57%) | 0.00% |
Average Days of Receivables |
25.60 | 28.87 | 26.96 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
15.19% | 25.02% | 16.00% |
Intangible Assets out of Total Assets |
0.24 | 0.26 | 0.25 |
Share Based Compensation of Revenue |
0.96% | 10.70% | (0.58%) |
Graham Net Nets |
0.01 | (0.01) | 0.00 |
Graham Number |
7.88 | 0.00 | 0.00 |
Earnings Yield |
2.63% | (7.09%) | (7.09%) |
Free Cash Flow Yield |
4.30% | 3.31% | 0.00% |
Revenue per Share |
23.22 | 19.81 | 0.00 |
Operating CF per Share |
1.61 | 0.93 | 0.00 |
Capex per Share |
(0.31) | (0.26) | 0.00 |
Free Cash Flow per Share |
1.29 | 0.67 | 0.00 |
Cash per Share |
1.05 | 0.08 | 0.00 |
Shareholders Equity per Share |
3.49 | 2.42 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
3.49 | 2.42 | 0.00 |
Free Cash Flow |
80.71 | 41.59 | 56.26 |
Working Capital |
60.93 | 7.86 | (8.41) |
Capital Expenditures |
(19.54) | (16.37) | (14.56) |
Net Current Asset Value |
26.90 | (18.85) | (81.70) |
EV/EBIT |
25.45 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.01 | 0.01 |
Price to Operating Income |
25.82 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.40 | 0.40 | 0.40 |
Cash ROIC |
28.46% | 26.90% | 63.50% |
Accounts Receivable Turnover |
14.58 | 14.09 | 0.00 |
Accounts Payable Turnover |
10.57 | 10.47 | 0.00 |
Inventory Turnover |
27.55 | 25.47 | 0.00 |
Average Days of Payables |
36.69 | 37.99 | 37.29 |
Days of Inventory on Hand |
13.69 | 15.04 | 16.00 |
Average Receivables |
99.38 | 87.21 | — |
Average Payables |
109.31 | 94.01 | — |
Average Inventory |
41.95 | 38.64 | — |
Average Assets |
366.73 | 295.99 | — |
Average Common Equity |
183.95 | 104.92 | — |
Columns are period end dates